1,916 material Form 8-K filings that 1,609 companies we cover made with the SEC in July 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
ImmunityBio announced on July 29, 2026 that the UAE's Emirates Drug Establishment granted marketing authorization for ANKTIVA in BCG-unresponsive non-muscle invasive bladder cancer and in metastatic non-small cell lung cancer after checkpoint inhibitor failure. The filing says this brings ANKTIVA's regulatory footprint to 34 countries, but it contains no revenue, sales, or financial results, so the direct financial effect on shareholders is not quantified.
UAE authorization granted with first registration in July 2026 and validity through July 2031.
Bladder cancer indication (with BCG) covers CIS with or without papillary tumors, described as the first worldwide to span the full spectrum of BCG-unresponsive disease.
Lung cancer indication (with checkpoint inhibitors) covers metastatic NSCLC after progression; median overall survival was 14.6 months in the 79-patient QUILT-3.055 study.
ImmunityBio's regional partner in the UAE is Modern Pharmaceutical Company.
AnaptysBio disclosed that the Court granted a joint stipulation setting the post-trial briefing schedule in its consolidated litigation with Tesaro and GlaxoSmithKline, following a trial held July 14-17, 2026. The filing contains no ruling on the merits, so the outcome of the dispute remains unresolved for shareholders.
Trial of the consolidated Tesaro litigation was held July 14-17, 2026.
The Court granted the parties' Joint Stipulation on July 28, 2026.
AnaptysBio's opening post-trial brief is due August 21, 2026, and post-trial argument is set for October 20, 2026.
An FDA advisory committee voted on July 29, 2026 that available evidence did not support the effectiveness of Deramiocel for cardiomyopathy in Duchenne muscular dystrophy patients. The vote is non-binding, and the FDA will consider it in its ongoing review of the Biologics License Application, whose PDUFA target action date remains August 22, 2026.
Committee vote on July 29, 2026 was 3 for, 9 against and 0 abstaining
The Committee's recommendation is non-binding; the FDA will weigh it with the full administrative record
PDUFA target action date for the BLA remains August 22, 2026
In a separate upper limb function discussion, the Committee's feedback was directionally supportive of Phase 3 HOPE-3 data, including the PUL 2.0 primary endpoint
Curis received written notice from Nasdaq on July 24, 2026 that it has regained compliance with the bid price rule and is in full compliance with the Nasdaq Hearings Panel's terms. The company will be subject to a one-year Discretionary Panel Monitor from July 24, 2026, meaning any new continued listing deficiency would lead to a delist determination and a hearing without additional time to cure, and there is no assurance it will remain listed.
Nasdaq notice dated July 24, 2026 confirms regained compliance with Listing Rule 5550(a)(2), the bid price rule
Discretionary Panel Monitor applies for one year from July 24, 2026 under Listing Rule 5815(d)(4)(A)
Any new continued listing deficiency during the monitor period gets no plan of compliance or extra time to cure
Filing states there can be no assurance Curis will remain listed on Nasdaq
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.